MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1

• Published in: Gastroenterology (New York, N.Y. 1943) Vol. 156; no. 6; pp. 1849 - 1861.e13
• Main Authors: Li, Hui, Li, Chia-Wei, Li, Xiaoqiang, Ding, Qingqing, Guo, Lei, Liu, Shuang, Liu, Chunxiao, Lai, Chien-Chen, Hsu, Jung-Mao, Dong, Qiongzhu, Xia, Weiya, Hsu, Jennifer L., Yamaguchi, Hirohito, Du, Yi, Lai, Yun-Ju, Sun, Xian, Koller, Paul B., Ye, Qinghai, Hung, Mien-Chie
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.05.2019
• Subjects: Animals; Antibodies, Monoclonal - therapeutic use; Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; B7-H1 Antigen - antagonists & inhibitors; B7-H1 Antigen - immunology; B7-H1 Antigen - metabolism; Carcinoma, Hepatocellular - drug therapy; Carcinoma, Hepatocellular - enzymology; Carcinoma, Hepatocellular - immunology; Cell Line, Tumor; Down-Regulation; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta - metabolism; Granzymes - metabolism; Hepatocellular Carcinoma; Imidazoles - pharmacology; Imidazoles - therapeutic use; Liver Neoplasms - drug therapy; Liver Neoplasms - enzymology; Liver Neoplasms - immunology; Male; Mice; Phosphorylation; Programmed Cell Death Ligand 1; Proto-Oncogene Proteins c-met - antagonists & inhibitors; Proto-Oncogene Proteins c-met - metabolism; Pyrrolidinones - pharmacology; Pyrrolidinones - therapeutic use; Quinolines - pharmacology; Quinolines - therapeutic use; TNF Receptor-Associated Factor 6 - immunology; TNF Receptor-Associated Factor 6 - metabolism; Triazines - pharmacology; Triazines - therapeutic use; Tumor Escape - drug effects; Tumor Necrosis Factor Receptor-Associated Factor 6; Ubiquitination; GSK3B; Y56F; Glycogen Synthase Kinase 3; HCC; Tumor Necrosis Factor Receptor-Associated Factor 6; p; shRNA; TRAF6; Y56; PD1; PDL1; WT; Programmed Cell Death Ligand 1; Hepatocellular Carcinoma
• ISSN: 0016-5085; 1528-0012; 1528-0012
• DOI: 10.1053/j.gastro.2019.01.252

Inhibitors of MET have not produced satisfactory outcomes in trials of patients with liver cancer. We investigated the mechanisms of liver tumor resistance to MET inhibitors in mice. We tested the effects of MET inhibitors tivantinib and capmatinib in the mouse hepatocellular carcinoma (HCC) cell line HCA-1 and in immune-competent and immunodeficient mice with subcutaneous tumors grown from this cell line. Tumors were collected from mice and tumor cells were analyzed by time-of-flight mass cytometry. We used short hairpin RNAs to weaken expression of MET in Hep3B, SK-HEP-1, HA59T, and HA22T liver cancer cell lines and analyzed cells by immunoblot, immunofluorescence, and immunoprecipitation assays. Mass spectrometry was used to assess interactions between MET and glycogen synthase kinase 3β (GSK3B), and GSK3B phosphorylation, in liver cancer cell lines. C57/BL6 mice with orthotopic tumors grown from Hep1-6 cells were given combinations of capmatinib or tivantinib and antibodies against programmed cell death 1 (PDCD1; also called PD1); tumors were collected and analyzed by immunofluorescence. We analyzed 268 HCCsamples in a tissue microarray by immunohistochemistry. Exposure of liver cancer cell lines to MET inhibitors increased their expression of PD ligand 1 (PDL1) and inactivated cocultured T cells. MET phosphorylated and activated GSK3B at tyrosine 56, which decreased the expression of PDL1 by liver cancer cells. In orthotopic tumors grown in immune-competent mice, MET inhibitors decreased the antitumor activity of T cells. However, addition of anti-PD1 decreased orthotopic tumor growth and prolonged survival of mice compared with anti-PD1 or MET inhibitors alone. Tissue microarray analysis of HCC samples showed an inverse correlation between levels of MET and PDL1 and a positive correlation between levels of MET and phosphorylated GSK3B. In studies of liver cancer cell lines and mice with orthotopic tumors, MET mediated phosphorylation and activated GSK3B, leading to decreased expression of PDL1. Combined with a MET inhibitor, anti-PD1 and anti-PDL1 produced additive effect to slow growth of HCCs in mice.